Quality of Life Among Polish Patients with Multiple Myeloma: A Cross-Sectional Study

13 November 2025 : Clinical Research

Magdalena Kurek

^{ABCDEF 1}, Tomasz Tatara

^{ADEF 1}, Jakub Świtalski

^{CDEF 2*}, Anna Augustynowicz

^{DE 3,4}, Barbara Łopyta^{DE 5}, Mariusz Gujski

^{DE 1}, Adam Fronczak^{ADEF 6}

DOI: 10.12659/MSM.948998

Med Sci Monit 2025; 31:e948998

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 6 Comparison of results by treatment method.

	Group 1 (chemotherapy)			Group 2 (autoHSCT)			Group 3 (supportive therapy)			P value
	Me	q1	q3	Me	q1	q3	Me	q1	q3	P value
Age	70	63.2	78	62	56.5	65	68	66	70	<0.001
Appetite loss	66.7	33.3	66.7	66.7	33.3	66.7	33.3	33.3	66.7	<0.001
Cognitive functioning	50	33.3	66.7	66.7	50	66.7	66.7	66.7	83.3	<0.001
Constipation	33.3	0	66.7	0	0	0	66.7	33.3	66.7	<0.001
Diarrhea	0	0	66.7	66.7	33.3	66.7	0	0	33.3	<0.001
Dyspnea	33.3	33.3	66.7	0	0	33.3	33.3	0	66.7	<0.001
Emotional functioning	50	33.3	66.7	58.3	41.7	75	75	66.7	91.7	<0.001
Fatigue	66.7	55.6	77.8	66.7	33.3	66.7	55.6	33.3	66.7	<0.001
Financial difficulties	33.3	33.3	66.7	33.3	16.7	33.3	33.3	0	33.3	<0.001
Global health status	50	33.3	50	50	37.5	54.2	58.3	50	66.7	<0.001
Insomnia	66.7	33.3	66.7	33.3	0	33.3	33.3	0	66.7	<0.001
Nausea and vomiting	50	33.3	66.7	33.3	16.7	66.7	16.7	16.7	50	<0.001
Pain	66.7	50	66.7	33.3	33.3	66.7	33.3	33.3	50	<0.001
Physical functioning	46.7	33.3	60	53.3	46.7	66.7	66.7	53.3	73.3	<0.001
Role functioning	50	33.3	66.7	33.3	33.3	66.7	66.7	50	66.7	<0.001
Social functioning	66.7	50	83.3	66.7	41.7	83.3	66.7	66.7	83.3	<0.001
Me – median; q1 – quartile 1; q3 – quartile 3.

Back to the Article